Future Trends in Tumor Marker Testing Market

Tumor markers are molecules found in urine, blood and body tissues. It is a protein which is found in large amounts in presence of forms of cancer. Thus measuring the levels of tumor markers may help in detecting the presence of cancer.  Presence of a tumor in body stimulates the production of tumor markers from tumor or non-tumor cells.

Brochure Download: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2253

Tumor marker testing market is categorized on the basis of diagnostic methods, type of cancer and technologies employed for cancer detection:

• Organ specific tumor marker: bladder, breast, colorectal, gastrointestinal, liver, lung, oral, ovarian, pancreatic, prostatic, skin testicular cancer, leukemia, lymphoma, and others

• Clinical laboratory methods for measuring tumor markers: Abbott diagnostics’ AxSYM, Roche Diagnostics System, Fischer Thermo Scientific B.R.A.H.M.S KRYPTOR and others

• New technologies for cancer diagnostics: Monoclonal antibodies, proteomics, new protein markers, stem cell markers, DNA microassays and others

• Clinical methods for cancer diagnosis: Screening, imaging, theranostics, sigmoidoscopy and others

Currently, cancer is the one of the leading causes of death in the developed countries like North America and Europe. North America holds the largest market share in tumor marker testing and is followed by Europe due to vast discoveries and innovations being carried out in these regions for detecting the cancer in its early stages. 

Some of the major factors driving tumor marker testing market are growing incidences of cancer disease, increase in aging population, tremendous ongoing research in the field of cancer detection and improved government reimbursement policies. The key deterrent holding back the market are involvement of high cost.

Some of the major players in tumor marker testing market are Abbott Diagnostics Ltd., Affymetrix, Inc., Agilent Technologies, Inc., Beckman, Dickinson and Company (BD) Diagnostics, BioCurex, BioModa, Inc., Clarient, Inc., Correlogic Systems, Inc., Epigenomics AG, Gen-Probe, Inc., Hologic, Inc., Roche Diagnostics Corp., and Veridex LLC.